We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $131.24 · 21 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Why Guardant Health (GH) Is Up 9.0% After ACS Adds Shield Test to Screening Guidelines - simplywall.st
Why Guardant Health (GH) Is Up 9.0% After ACS Adds Shield Test to Screening Guidelines simplywall.st
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook Kavout
Guardant Health director sells $130,060 of common stock - Investing.com
Guardant Health director sells $130,060 of common stock Investing.com
Guardant Health (GH) director sells 1,000 shares, retains 639 - Stock Titan
Guardant Health (GH) director sells 1,000 shares, retains 639 Stock Titan
Is It Too Late To Consider Guardant Health (GH) After A 246% One Year Surge? - simplywall.st
Is It Too Late To Consider Guardant Health (GH) After A 246% One Year Surge? simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 29. | After market close (AMC) | $-0.39 | — | — | $314.97M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.77 | — | — | $203.47M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-2.66 | — | — | $537.2M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-1.78 | — | — | $345.73M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 26. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 09. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 05. 09. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 05. 08. | Evercore ISI Group | — | Maintain | In-Line → In-Line | — | Evercore ISI Group: In-Line |
| 2026. 04. 15. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 4,229,531 | $390.68B | 0.33% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 2,171,903 | $221.84B | 0.35% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,499,169 | $153.13B | 0.25% | — | New position |
| 4 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 695,940 | $64.28B | 0.12% | — | New position |